Pharvaris (PHVS) Net Equity Issued and Repurchased (2020 - 2025)

Pharvaris' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $200.3 million for Q3 2025.

• Quarterly Net Equity Issued and Repurchased rose 17806.98% year-over-year to $200.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $201.5 million (up 100.0% YoY) and the FY2022 annual result came in at $10.1 million, down 94.54% from the prior year.
• Net Equity Issued and Repurchased was $200.3 million for Q3 2025 at Pharvaris, up from $418.83 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $200.3 million in Q3 2025 and bottomed at -$69762.2 billion in Q3 2023.
• A 5-year average of -$5366.3 billion and a median of $97449.6 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 315574464166.85% — and 2025, when it soared 17806.98%.
• Pharvaris' Net Equity Issued and Repurchased stood at -$470309.3 in 2021, then jumped by 104.7% to $22106.4 in 2022, then plunged by 315574464166.85% to -$69762.2 billion in 2023, then jumped by 100.0% to $1.1 million in 2024, then surged by 17806.98% to $200.3 million in 2025.
• Business Quant data shows PHVS's Net Equity Issued and Repurchased at $200.3 million in Q3 2025, $418.83 in Q2 2025, and $30597.2 in Q1 2025.